| Azacitidine and venetoclax in previously untreated acute myeloid leukemia CD DiNardo, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, AH Wei, ... New England Journal of Medicine 383 (7), 617-629, 2020 | 1875 | 2020 |
| Daratumumab, lenalidomide, and dexamethasone for multiple myeloma MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ... New England Journal of Medicine 375 (14), 1319-1331, 2016 | 1597 | 2016 |
| Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML AE Perl, G Martinelli, JE Cortes, A Neubauer, E Berman, S Paolini, ... New England Journal of Medicine 381 (18), 1728-1740, 2019 | 1064 | 2019 |
| Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma MV Mateos, MA Dimopoulos, M Cavo, K Suzuki, A Jakubowiak, S Knop, ... New England Journal of Medicine 378 (6), 518-528, 2018 | 981 | 2018 |
| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a … JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... The lancet oncology 15 (11), 1195-1206, 2014 | 895 | 2014 |
| Integrated molecular analysis of adult T cell leukemia/lymphoma K Kataoka, Y Nagata, A Kitanaka, Y Shiraishi, T Shimamura, J Yasunaga, ... Nature genetics 47 (11), 1304-1315, 2015 | 813 | 2015 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 692 | 2019 |
| Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial MV Mateos, M Cavo, J Blade, MA Dimopoulos, K Suzuki, A Jakubowiak, ... The Lancet 395 (10218), 132-141, 2020 | 413 | 2020 |
| CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? WS Kim, SY Song, YC Ahn, YH Ko, CH Baek, DY Kim, SS Yoon, HG Lee, ... Annals of Oncology 12 (3), 349-352, 2001 | 277 | 2001 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 245 | 2019 |
| Pan-cancer analysis of whole genomes. S Hirano, L Yang, M Juul, CA Purdie, BP O'Neill, R Kabbe, ... Nature 578 (DKFZ-2020-01051), 82-93, 2020 | 242 | 2020 |
| Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study LE Budde, S Assouline, LH Sehn, SJ Schuster, SS Yoon, DH Yoon, ... Journal of Clinical Oncology 40 (5), 481-491, 2022 | 232 | 2022 |
| Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T … SJ Schuster, NL Bartlett, S Assouline, SS Yoon, F Bosch, LH Sehn, ... Blood 134, 6, 2019 | 206 | 2019 |
| Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study WK Kang, C Park, HL Yoon, WS Kim, SS Yoon, MH Lee, K Park, K Kim, ... Human gene therapy 12 (6), 671-684, 2001 | 189 | 2001 |
| Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma WS Kim, MM Kim, HJ Choi, SS Yoon, MH Lee, K Park, CH Park, WK Kang Investigational new drugs 19, 81-83, 2001 | 186 | 2001 |
| Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia DY Kim, YD Joo, SN Lim, SD Kim, JH Lee, JH Lee, DH Kim, K Kim, ... Blood, The Journal of the American Society of Hematology 126 (6), 746-756, 2015 | 175 | 2015 |
| Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo … JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... The Lancet Haematology 3 (11), e506-e515, 2016 | 164 | 2016 |
| The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment E Rondeau, M Scully, G Ariceta, T Barbour, S Cataland, N Heyne, ... Kidney International 97 (6), 1287-1296, 2020 | 156 | 2020 |
| Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment PG Richardson, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... Blood, The Journal of the American Society of Hematology 127 (6), 713-721, 2016 | 156 | 2016 |
| 11C-Pittsburgh B PET Imaging in Cardiac Amyloidosis SP Lee, ES Lee, H Choi, HJ Im, Y Koh, MH Lee, JH Kwon, JC Paeng, ... JACC: Cardiovascular Imaging 8 (1), 50-59, 2015 | 155 | 2015 |
